A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Voyager Therapeutics, Inc.
VYGR
$178M
Mkt Cap
$3.10
+0.32%
Voyager Therapeutics, Inc. (VYGR) has a 5-year average return on invested capital (ROIC) of -21.3%. This is below average and may indicate limited pricing power.
Voyager Therapeutics, Inc. (VYGR) has a market capitalization of $172M. It is classified as a small-cap stock.
Voyager Therapeutics, Inc. (VYGR) does not currently pay a regular dividend.
Voyager Therapeutics, Inc. (VYGR) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Voyager Therapeutics, Inc. (VYGR) reported annual revenue of $80 million in its most recent fiscal year, based on SEC EDGAR filings.
Voyager Therapeutics, Inc. (VYGR) has a net profit margin of -81.3%. The company is currently unprofitable.
Voyager Therapeutics, Inc. (VYGR) generated $-19 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ITEM 1. BUSINESS We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Our pipeline includes programs for Alzheimer’s disease, or AD; Friedreich’s ataxia, or FA; Parkinson’s disease; and multiple other diseases of the central nervous system, or CNS. Many of our programs are derived from our TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which we have used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Some of our programs are wholly-owned, and some are advancing with licensees and collaborators including Alexion, AstraZeneca Rare Disease, or Alexion; Novartis Pharma AG, or Novartis; and Neurocrine Biosciences, Inc., or Neurocrine.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 31M | 80M | 250M | 41M | 37M | 171M |
| Net Income | -127M | -65M | 132M | -46M | -71M | 37M |
| EPS | $-2.17 | $-1.13 | $2.97 | $-1.21 | $-1.89 | $0.98 |
| Free Cash Flow | -119M | -19M | 75M | -15M | -55M | -109M |
| ROIC | -1016.7% | -21.7% | 51.1% | -78.6% | -74.9% | 17.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.31 | 0.49 | 1.70 | 1.04 | 0.70 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -140M | -83M | 122M | -51M | -74M | 27M |
| Operating Margin | -447.7% | -104.1% | 48.8% | -124.3% | -196.8% | 16.0% |
| ROE | -57.7% | -24.3% | 56.0% | -78.6% | -74.9% | 23.8% |
| Shares Outstanding | 56M | 58M | 45M | 38M | 38M | 37M |
| Metric | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | N/A | N/A | N/A | N/A | 104M | 171M | 37M | 41M | 250M | 80M | 31M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -20M | -41M | -72M | -91M | -52M | 27M | -74M | -51M | 122M | -83M | -140M |
| Op. Margin | N/A | N/A | N/A | N/A | -49.5% | 16.0% | -196.8% | -124.3% | 48.8% | -104.1% | -447.7% |
| Net Income | -38M | -40M | -71M | -88M | -44M | 37M | -71M | -46M | 132M | -65M | -127M |
| Net Margin | N/A | N/A | N/A | N/A | -41.8% | 21.5% | -190.3% | -113.4% | 52.9% | -81.3% | -404.8% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||
| ROIC | -22.6% | -29.6% | -52.7% | -154.9% | -43.8% | 17.7% | -74.9% | -78.6% | 51.1% | -21.7% | N/M |
| ROE | -22.6% | -29.6% | -52.7% | -190.1% | -43.8% | 23.8% | -74.9% | -78.6% | 56.0% | -24.3% | -57.7% |
| ROA | -16.7% | -21.2% | -38.3% | -49.9% | -12.3% | 14.0% | -36.7% | -29.1% | 37.7% | -17.5% | -44.0% |
| Cash Flow | |||||||||||
| Op. Cash Flow | 41M | -42M | -61M | -16M | 49M | -97M | -54M | -13M | 78M | -15M | -117M |
| Free Cash Flow | 40M | -48M | -65M | -20M | 41M | -109M | -55M | -15M | 75M | -19M | -119M |
| Owner Earnings | 37M | -49M | -72M | -34M | 30M | -115M | -70M | -28M | 62M | -35M | -136M |
| CapEx | 1.0M | 5.0M | 4.0M | 4.3M | 7.7M | 12M | 1.6M | 2.5M | 3.3M | 3.5M | 2.1M |
| Maint. CapEx | 600K | 612K | 1.6M | 2.1M | 2.8M | 3.8M | 5.2M | 6.2M | 4.4M | 4.7M | 4.7M |
| Growth CapEx | 430K | 4.4M | 2.4M | 2.2M | 5.0M | 8.3M | 0 | 0 | 0 | 0 | 0 |
| D&A | 600K | 612K | 1.6M | 2.1M | 2.8M | 3.8M | 5.2M | 6.2M | 4.4M | 4.7M | 4.7M |
| CapEx/OCF | 2.5% | N/A | N/A | N/A | 15.9% | N/A | N/A | N/A | 4.2% | N/A | 0.0% |
| Capital Allocation | |||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 4.0M | 6.3M | 9.2M | 16M | 16M | 15M | 11M | 9.3M | 11M | 15M | 15M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -209M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 209M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.36 | 0.39 | 0.38 | 2.81 | 2.56 | 0.70 | 1.04 | 1.70 | 0.49 | 0.31 | 0.00 |
| Interest Coverage | -61.0 | -42.3 | -58.6 | -27.5 | -8.0 | 16.5 | -188.8 | -28.4 | 10.4 | -4.5 | -4.5 |
| Equity | 169M | 136M | 134M | 46M | 100M | 154M | 95M | 59M | 236M | 300M | 220M |
| Total Assets | 229M | 190M | 184M | 177M | 355M | 262M | 194M | 159M | 351M | 393M | 288M |
| Total Liabilities | 60M | 54M | 50M | 131M | 255M | 107M | 99M | 100M | 115M | 93M | 68M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -50M | -90M | -161M | -269M | -313M | -276M | -347M | -394M | -261M | -326M | -326M |
| Working Capital | 172M | 165M | 156M | 131M | 229M | 171M | 86M | 52M | 255M | 227M | 227M |
| Current Assets | 196M | 179M | 172M | 162M | 305M | 198M | 137M | 124M | 320M | 277M | 277M |
| Current Liabilities | 24M | 14M | 16M | 32M | 76M | 27M | 51M | 73M | 65M | 50M | 50M |
| Per Share Data | |||||||||||
| EPS | 9.14 | 1.59 | -2.64 | -2.75 | -1.21 | 0.98 | -1.89 | -1.21 | 2.97 | -1.13 | -2.17 |
| Owner EPS | 1.37 | -1.53 | -2.70 | -1.05 | 0.84 | -3.08 | -1.86 | -0.73 | 1.40 | -0.61 | -2.45 |
| Book Value | 6.30 | 4.22 | 5.01 | 1.45 | 2.76 | 4.12 | 2.52 | 1.54 | 5.30 | 5.21 | 3.95 |
| Cash Flow/Share | 1.54 | -1.32 | -2.29 | -0.49 | 1.35 | -2.58 | -1.42 | -0.33 | 1.75 | -0.27 | -2.20 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 26.8M | 32.2M | 26.8M | 32.1M | 36.0M | 37.5M | 37.7M | 38.4M | 44.6M | 57.5M | 55.6M |
| Valuation | |||||||||||
| P/E Ratio | 2.3 | 8.2 | N/A | N/A | N/A | 7.7 | N/A | N/A | 3.0 | N/A | -1.4 |
| P/FCF | 14.2 | N/A | N/A | N/A | 12.3 | N/A | N/A | N/A | 5.3 | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 3.4 | 3.1 | 3.4 | 6.3 | 5.0 | 1.8 | 1.1 | 3.6 | 1.7 | 1.1 | 0.8 |
| Price/Sales | N/A | N/A | N/A | N/A | 6.2 | 2.4 | 4.6 | 5.4 | 1.5 | 5.5 | 5.5 |
| FCF Yield | 7.0% | -11.3% | -14.4% | -6.9% | 8.2% | -38.5% | -52.6% | -7.0% | 19.0% | -5.7% | -69.0% |
| Market Cap | 573M | 421M | 454M | 293M | 502M | 282M | 105M | 213M | 393M | 330M | 172M |
| Avg. Price | 23.08 | 12.62 | 12.65 | 18.35 | 17.86 | 11.18 | 4.54 | 5.78 | 8.63 | 7.64 | 3.10 |
| Year-End Price | 21.35 | 13.08 | 16.96 | 9.12 | 13.94 | 7.53 | 2.78 | 5.56 | 8.81 | 5.74 | 3.10 |
Voyager Therapeutics, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +21.1%.
Voyager Therapeutics, Inc. (VYGR) has a debt-to-equity ratio of 0.31. This indicates a conservatively financed balance sheet.
Voyager Therapeutics, Inc. (VYGR) reported earnings per share (EPS) of $-1.13 in its most recent fiscal year.
Voyager Therapeutics, Inc. (VYGR) has a return on equity (ROE) of -24.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 10 years of financial data for Voyager Therapeutics, Inc. (VYGR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Voyager Therapeutics, Inc. (VYGR) has a book value per share of $5.21, based on its most recent annual SEC filing.